Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viatris Inc. VTRS

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:Paul MacDonALD- BNN - Don't BUY

Lorne and Paul need to go out for a coffee and discuss further.  I have no issue holding and not worrying about this one for many years, at some point its valuation will attract cyclical value...read more

Paul MacDonALD- BNN - Don't BUY

DON'T BUY Viatris(VTRS-Q) 02/02/2022 at 07:00pm   Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk...read more

RE:RE:Lorne Steinberg on BNN - BUY

Still banging the drum for the stock. PAST TOP PICK Viatris(VTRS-Q) (A Top Pick Dec 22/20, Down 24%) By far the cheapest cost ...read more

RE:Lorne Steinberg on BNN - BUY

STRONG BUY Viatris(VTRS-Q) PE is around 5. Cheapest stock in his portfolio. First quarter, they underdelivered and the stock was punished. Last quarter, management delivered....read more

Lorne Steinberg on BNN - BUY

Viatris (VTRS-Q) June 28, 2021   It is the cheapest stock he owns. They came to market and disappointed with their first quarter. The are being punished by the street. They are now a...read more

Viatris Posion

Rajiv Malik president up for price fixing, Chairmen Robert Coury Epipen scandal and drew attiontion for FDA for bad practices and blamed it all on former CEO heather Bresch.  Pfizer made a deal...read more

RE:RE:More info....COMMENTS

Wrong they lowered that est. and will also put options for apr. 23rd a desperate move for a company around only 3 months.  They are in trouble already, but with Robert Coury at the helm you could...read more